Cellectis Swings to Q3 Net Loss of $61.47 Million

• Cellectis swung to a third-quarter net loss of $61.47 million from a year-earlier profit of $589,000.
• Revenue fell 89% year over year to $3.76 million.
• Cash, cash equivalents and term deposits totaled $149 million at September 30, with runway into second-half 2028 contingent on restructuring.
• Planned workforce reductions could reach 70% during 2026 and 2027 under the shift to in vivo gene editing.
• Initial clinical data for .HEAL-101 remain expected in second-half 2027, with the investigator-initiated Phase 1 trial in China on schedule.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectis SA published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121924OMX_____CNEWS_FR_GNW9876992_fr) on November 13, 2026, and is solely responsible for the information contained therein.